Table IV.
Information on 35 EGFR mutations detected by direct sequencing and the EGFR-TKI response of the patients.
| Amino acid/deletion type | Nucleotide | No. | Histology ADC/SCC | Response CR/PR/SD/PD/NA |
|---|---|---|---|---|
| Exon 18 | ||||
| G719S | G2155A | 1 | 2/0 | 0/1/0/0/0 |
| Exon 19 | 23 | 20/3 | 2/6/10/1/4 | |
| E746-A750 del | 2,235-2,249 | – | – | – |
| 2,236-2,250 | 13 | 11/2 | 0/3/7/1/2 | |
| E746-S752 dela | 2,236-2,256 | 1 | 1/0 | 1/0/0/0/0 |
| L747-E749 del | 2,239-2,247 | 1 | 1/0 | 1/0/0/0/0 |
| L747-L751 del | 2,239-2,253 | – | – | – |
| 2,240-2,254 | 3 | 3/0 | 0/2/0/0/1 | |
| L747-P753 ins S | 2,240-2,257 | 3 | 3/0 | 0/1/2/0/0 |
| T751-I759 ins Sa | 2,252-2,275 T2276G | 1 | 1/0 | 0/0/1/0/0 |
| K757-L760 ins Na | 2,271-2,279 | 1 | 0/1 | 0/0/0/0/1 |
| Exon 21 | ||||
| L858R | T2573G | 11 | 11/0 | 0/2/8/0/1 |
| Total EGFR mutations | – | 35 | 32/3 | 2/9/18/1/5 |
a
Exon 19 deletion that was not identified by Scorpion-ARMS and cobas v2. EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; ADC, adenocarcinoma; SCC, squamous cell carcinoma; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NA, no assessable patients; del, deletion; ins, insertion.